|
|
|
Dr Robin Robinson
Director, BARDA, ASPR
US Department of Health and Human Services
Daniel Adams
Chief Executive Officer
Protein Sciences
John Trizzino
Senior Vice President, International & Government Alliances
Novavax
Dr Klaus Stohr
Vice President, Global Head, Influenza Strategy Liaison
Novartis
Dr Samuel Bogoch
Chairman
Replikins
|
|
|
|
North America’s most influential influenza congress
The influenza vaccine is the fastest growing segment in the adult vaccine market. Annually, more than 3.5 million people die of influenza. By 2016, this market is expected to grow to $4.4 billion. H1N1 remains the most immediate threat. In the US, President Obama responded by earmarking $1.8 billion to fight the swine flu.
No one knows the amount of damage the H1N1 outbreak may cause during Fall in the Northern Hemisphere. Governments & international organizations are clamoring for effective vaccines & antivirals to protect their populations. In recent years, influenza vaccine development & alternative treatments like antivirals have evolved tremendously as pharma & biotech companies work hard to develop new technology & alternative methods from traditional egg-based vaccines. The key drivers impacting the development of influenza vaccines & related therapies include cost effectiveness, capacity & adaptability.
The US accounts for over 50% of the global vaccine market. With so much talent & innovation taking place & heightened concern due to the global swine flu pandemic, Influenza Congress USA is both timely & necessary.
» Download the brochure
|
“An excellent lineup of speakers. Event was an outstanding learning and networking opportunity for me and my institution”
Cindy Gustafson, Chief Financial Officer, Seattle Biomedical Research Institute
|
|
“I thought the meeting was a great success and I have never attended a conference that was better organized. I thoroughly enjoyed it and felt that it was time very well spent”
Rick Hancock, Executive Vice President, Europe, Althea Technologies
|
» Register today and save!
|
|
|
Key topics:
- Pandemic influenza A (H1N1) overview
- Pandemic preparedness
- Vaccine development & commercialization strategies- pandemic, universal & seasonal
- Antivirals
- Adjuvants
- Alternatives to traditional egg-based vaccines
- Production, manufacturing & capacity
- Collaboration & partnerships
» Book now
» Contact us
|
Who’s attending?
- Pharma vaccine & antiviral manufacturers
- Biotechs
- Government, public health & NGOs
- Research institutes & academia
- Contract service organizations
- Venture capitalists
- Logistics & cold chain supply
- Equipment manufacturers
- Drug discovery & delivery platforms
- Management, technology & regulatory consultants
» Register early and save
|
*Calling all service providers*
Influenza Congress USA 2009 should be your platform for business development platform in 2009.
Sponsoring Influenza Congress USA 2009 will put your organization at the forefront of influenza planning and development.
» Find out more about sponsorship
» Learn how you can benefit
|
|
|
|
|
|
|
|
|
|
